 Connection
Daniel Merrick to Protein Kinase Inhibitors
This is a "connection" page, showing publications Daniel Merrick has written about Protein Kinase Inhibitors.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.153 |
|
|
|
-
McCoach CE, Le AT, Gowan K, Jones K, Schubert L, Doak A, Estrada-Bernal A, Davies KD, Merrick DT, Bunn PA, Purcell WT, Dziadziuszko R, Varella-Garcia M, Aisner DL, Camidge DR, Doebele RC. Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer. Clin Cancer Res. 2018 07 15; 24(14):3334-3347.
Score: 0.102
-
Kleczko EK, Le AT, Hinz TK, Nguyen TT, Navarro A, Hu CJ, Selman AM, Clambey ET, Merrick DT, Lu S, Weiser-Evans M, Nemenoff RA, Heasley LE. Novel EGFR-mutant mouse models of lung adenocarcinoma reveal adaptive immunity requirement for durable osimertinib response. Cancer Lett. 2023 03 01; 556:216062.
Score: 0.036
-
Karoor V, Le M, Merrick D, Dempsey EC, Miller YE. Vascular endothelial growth factor receptor 2-targeted chemoprevention of murine lung tumors. Cancer Prev Res (Phila). 2010 Sep; 3(9):1141-7.
Score: 0.015
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|